Association of Chinese visceral adiposity index and high-sensitivity C-reactive protein with the risk of digestive malignancies

Shuqing CUI; Chao MA; Jiaxing LI; Yunpeng LI; Ze WANG; Fei TIAN; Hong JI; Xinyu GE; Shouling WU; Xiangming MA

doi:10.12449/JCH250723

Volume 41 Issue 7

Jul. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(7): 1380-1387

PDF( 1028 KB)

Association of Chinese visceral adiposity index and high-sensitivity C-reactive protein with the risk of digestive malignancies

DOI: 10.12449/JCH250723

1.
Department of Hepatobiliary Surgery，Kailuan General Hospital Affiliated to North China University of Science and Technology，Tangshan，Hebei 063000，China
2.
Health Care Center，Kailuan General Hospital Affiliated to North China University of Science and Technology，Tangshan，Hebei 063000，China
3.
Department of Hepatobiliary Surgery，The Affiliated Hospital of North China University of Science and Technology，Tangshan，Hebei 063000，China
4.
Department of Oncology Radiotherapy and Chemotherapy，The Affiliated Hospital of North China University of Science and Technology，Tangshan，Hebei 063000，China

Research funding:

2023 Medical Science Research Project Plan of Hebei Province (20230194)

More Information

Corresponding author: MA Xiangming， brighter_ma@163.com （ORCID： 0009-0005-4182-7244）
Received Date: 2024-12-17
Accepted Date: 2025-02-20
Published Date: 2025-07-25

Abstract

Abstract

Objective To investigate the association of Chinese visceral adiposity index （CVAI） and high-sensitivity C-reactive protein （hs-CRP） with the risk of digestive malignancies in the Kailuan study population， and to provide a basis for the prevention and control of digestive malignancies in the population. Methods A prospective cohort study was conducted， and a total of 94 377 Kailuan workers who participated in the 2006 health examination， had no history of cancer， and had complete data on CVAI， CRP， and related covariates were selected as the observation cohort. According to the levels of CVAI and CRP， the subjects were divided into low CVAI+CRP≤3 mg/L group ［CVAI（-）CRP（-） group］， low CVAI+CRP>3 mg/L group ［CVAI（-）CRP（+） group］， high CVAI+CRP≤3 mg/L group ［CVAI（+）CRP（-） group］， and high CVAI+CRP>3 mg/L group ［CVAI（+）CRP（+） group］. An analysis of variance was used for comparison of normally distributed continuous data between groups， and the non-parametric Kruskal-Wallis H test was used for comparison of continuous data with skewed distribution between groups； the chi-square test was used for comparison of categorical data between groups. The Cox proportional-hazards regression model was used to assess the impact of CVAI and CRP alone or in combination on the risk of digestive malignancies. Results There were significant differences between the four groups in age， male/female ratio， total cholesterol， triglycerides， high-density lipoprotein cholesterol， systolic blood pressure， diastolic blood pressure， fasting blood glucose， high-sensitivity C-reactive protein， waist circumference， body mass index， marital status， alcohol consumption， smoking， reported income， and physical exercise （all P<0.05）. During a mean follow-up time of 14.08±2.76 years， 2 043 new-onset cases of digestive malignancies were identified by the end of follow-up on December 31， 2021. The Cox proportional-hazards regression model showed that after adjustment for CRP and other factors， compared with the low CVAI group， the high CVAI group had a hazard ratio （HR） of 1.34 （95% confidence interval ［CI］： 1.23‍ ‍—‍ ‍1.47） for the risk of digestive malignancies. After adjustment for CVAI and other factors， compared with the CRP≤3 mg/L group， the CRP>3 mg/L group had an HR of 1.14 （95%CI： 1.02‍ ‍—‍ ‍1.28） for the risk of digestive malignancies. Compared with the CVAI（-）CRP（-） group （n=40 978）， the CVAI（-）CRP（+） group （n=6 210）， the CVAI（+）CRP（-） group （n=36 502）， and the CVAI（+）CRP（+） group （n=10 687） had an HR of 1.05 （95%CI： 1.01‍ ‍—‍ ‍1.09，P<0.05）， 1.32 （95%CI： 1.20‍ ‍—‍ ‍1.45， P<0.05）， and 1.48 （95%CI： 1.28‍ ‍—‍ ‍1.70， P<0.05）， respectively， for the risk of digestive malignancies. As for digestive malignancies at specific locations， the CVAI（+）CRP（+） group had an increased risk of liver cancer， gastric cancer， pancreatic cancer， colorectal cancer， and small intestinal cancer with an HR of 1.35 （95%CI： 1.05‍ ‍—‍ ‍1.81， P<0.05）， 1.48 （95%CI： 1.09‍ ‍—‍ ‍2.00， P<0.05）， 1.60 （95%CI： 1.07‍ ‍—‍ ‍2.41， P<0.05）， 1.76 （1.40‍ ‍—‍ ‍2.21， P<0.05）， and 3.85（95%CI：1.43‍ ‍—‍ ‍10.33， P<0.05）， respectively. Conclusion A high level of CVAI， a high level of CRP， and high levels of CVAI and CRP in combination can all increase the risk of digestive malignancies， among which the high levels of CVAI and CRP in combination may lead to a higher risk.
- China Visceral Fat Index,
- C-Reactive Protein,
- Digestive System Neoplasms,
- Cohort Studies

FullText(HTML)

References(45)

References

[1]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74( 3): 229- 263. DOI: 10.3322/caac.21834.
[2]	BROWN JC, MEYERHARDT JA. Obesity and energy balance in GI cancer[J]. J Clin Oncol, 2016, 34( 35): 4217- 4224. DOI: 10.1200/JCO.2016.66.8699.
[3]	BRITTON KA, MASSARO JM, MURABITO JM, et al. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality[J]. J Am Coll Cardiol, 2013, 62( 10): 921- 925. DOI: 10.1016/j.jacc.2013.06.027.
[4]	MURPHY RA, BUREYKO TF, MILJKOVIC I, et al. Association of total adiposity and computed tomographic measures of regional adiposity with incident cancer risk: A prospective population-based study of older adults[J]. Appl Physiol Nutr Metab, 2014, 39( 6): 687- 692. DOI: 10.1139/apnm-2013-0360.
[5]	AMATO MC, GIORDANO C, GALIA M, et al. Visceral adiposity index: A reliable indicator of visceral fat function associated with cardiometabolic risk[J]. Diabetes Care, 2010, 33( 4): 920- 922. DOI: 10.2337/dc09-1825.
[6]	ANOOP S, KRAKAUER J, KRAKAUER N, et al. A body shape index significantly predicts MRI-defined abdominal adipose tissue depots in non-obese Asian Indians with type 2 diabetes mellitus[J]. BMJ Open Diabetes Res Care, 2020, 8( 1): e001324. DOI: 10.1136/bmjdrc-2020-001324.
[7]	WANG YY, ZHAO XD, CHEN Y, et al. Visceral adiposity measures are strongly associated with cardiovascular disease among female participants in Southwest China: A population-based prospective study[J]. Front Endocrinol(Lausanne), 2022, 13: 969753. DOI: 10.3389/fendo.2022.969753.
[8]	WU XY, WANG CQ, LV DL, et al. Associations between Chinese visceral adiposity index and risks of all-cause and cause-specific mortality: A population-based cohort study[J]. Diabetes Obes Metab, 2024, 26( 4): 1264- 1272. DOI: 10.1111/dom.15424.
[9]	HANAHAN D, WEINBERG RA. The hallmarks of cancer[J]. Cell, 2000, 100( 1): 57- 70. DOI: 10.1016/s0092-8674(00)81683-9.
[10]	ASEGAONKAR SB, ASEGAONKAR BN, TAKALKAR UV, et al. C-reactive protein and breast cancer: New insights from old molecule[J]. Int J Breast Cancer, 2015, 2015: 145647. DOI: 10.1155/2015/145647.
[11]	SONG MM, LIU T, LIU H, et al. Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: A large prospective study[J]. BMC Cancer, 2022, 22( 1): 853. DOI: 10.1186/s12885-022-09939-w.
[12]	KIM S, SONG SH, KIM YS, et al. The association between predicted inflammatory status and colorectal adenoma[J]. Sci Rep, 2020, 10( 1): 2433. DOI: 10.1038/s41598-020-59271-1.
[13]	ISLAMI F, GODING SAUER A, MILLER KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States[J]. CA Cancer J Clin, 2018, 68( 1): 31- 54. DOI: 10.3322/caac.21440.
[14]	BEN-AHARON I, van LAARHOVEN HWM, FONTANA E, et al. Early-onset cancer in the gastrointestinal tract is on the rise-evidence and implications[J]. Cancer Discov, 2023, 13( 3): 538- 551. DOI: 10.1158/2159-8290.CD-22-1038.
[15]	ARNOLD M, ABNET CC, NEALE RE, et al. Global burden of 5 major types of gastrointestinal cancer[J]. Gastroenterology, 2020, 159( 1): 335- 349. e 15. DOI: 10.1053/j.gastro.2020.02.068.
[16]	ESTERSON YB, GRIMALDI GM. Radiologic imaging in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Clin Liver Dis, 2018, 22( 1): 93- 108. DOI: 10.1016/j.cld.2017.08.005.
[17]	SAVERYMUTTU SH, JOSEPH AE, MAXWELL JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis[J]. Br Med J(Clin Res Ed), 1986, 292( 6512): 13- 15. DOI: 10.1136/bmj.292.6512.13.
[18]	AMER A, FRANCHI L, KANNEGANTI TD, et al. Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf[J]. J Biol Chem, 2006, 281( 46): 35217- 35223. DOI: 10.1074/jbc.M604933200.
[19]	HURSTING SD, DIGIOVANNI J, DANNENBERG AJ, et al. Obesity, energy balance, and cancer: New opportunities for prevention[J]. Cancer Prev Res(Phila), 2012, 5( 11): 1260- 1272. DOI: 10.1158/1940-6207.CAPR-12-0140.
[20]	BHASKARAN K, DOUGLAS I, FORBES H, et al. Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5·24 million UK adults[J]. Lancet, 2014, 384( 9945): 755- 765. DOI: 10.1016/S0140-6736(14)60892-8.
[21]	FOX CS, MASSARO JM, HOFFMANN U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study[J]. Circulation, 2007, 116( 1): 39- 48. DOI: 10.1161/CIRCULATIONAHA.106.675355.
[22]	LU YJ, ZHAO YC, LIU KY, et al. A validated estimate of visceral adipose tissue volume in relation to cancer risk[J]. J Natl Cancer Inst, 2024, 116( 12): 1942- 1951. DOI: 10.1093/jnci/djae193.
[23]	XU FQ, XU QY, ZHU ZJ, et al. Visceral and ectopic fat are more predictively associated with primary liver cancer than overall obesity from genetic sights: A Mendelian randomization study[J]. Int J Cancer, 2024, 154( 3): 530- 537. DOI: 10.1002/ijc.34751.
[24]	LU Y, TANG HB, HUANG PY, et al. Assessment of causal effects of visceral adipose tissue on risk of cancers: A Mendelian randomization study[J]. Int J Epidemiol, 2022, 51( 4): 1204- 1218. DOI: 10.1093/ije/dyac025.
[25]	GRIVENNIKOV SI, GRETEN FR, KARIN M. Immunity, inflammation, and cancer[J]. Cell, 2010, 140( 6): 883- 899. DOI: 10.1016/j.cell.2010.01.025.
[26]	ALLIN KH, NORDESTGAARD BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer[J]. Crit Rev Clin Lab Sci, 2011, 48( 4): 155- 170. DOI: 10.3109/10408363.2011.599831.
[27]	ALLIN KH, BOJESEN SE, NORDESTGAARD BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer[J]. J Clin Oncol, 2009, 27( 13): 2217- 2224. DOI: 10.1200/JCO.2008.19.8440.
[28]	SROUR B, KAAKS R, JOHNSON T, et al. Ageing-related markers and risks of cancer and cardiovascular disease: A prospective study in the EPIC-Heidelberg cohort[J]. Eur J Epidemiol, 2022, 37( 1): 49- 65. DOI: 10.1007/s10654-021-00828-3.
[29]	COUSSENS LM, WERB Z. Inflammation and cancer[J]. Nature, 2002, 420( 6917): 860- 867. DOI: 10.1038/nature01322.
[30]	IL’YASOVA D, COLBERT LH, HARRIS TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14( 10): 2413- 2418. DOI: 10.1158/1055-9965.EPI-05-0316.
[31]	ALLIN KH, BOJESEN SE, NORDESTGAARD BG. Inflammatory biomarkers and risk of cancer in 84, 000 individuals from the general population[J]. Int J Cancer, 2016, 139( 7): 1493- 1500. DOI: 10.1002/ijc.30194.
[32]	VAN’T KLOOSTER CC, RIDKER PM, HJORTNAES J, et al. The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: A cohort study[J]. Eur Heart J, 2019, 40( 48): 3901- 3909. DOI: 10.1093/eurheartj/ehz587.
[33]	ZHU M, MA ZM, ZHANG X, et al. C-reactive protein and cancer risk: A pan-cancer study of prospective cohort and Mendelian randomization analysis[J]. BMC Med, 2022, 20( 1): 301. DOI: 10.1186/s12916-022-02506-x.
[34]	PONCE CB, SCHERER D, BRINSTER R, et al. Gallstones, body mass index, C-reactive protein, and gallbladder cancer: Mendelian randomization analysis of Chilean and European genotype data[J]. Hepatology, 2021, 73( 5): 1783- 1796. DOI: 10.1002/hep.31537.
[35]	ALLIN KH, NORDESTGAARD BG, ZACHO J, et al. C-reactive protein and the risk of cancer: A mendelian randomization study[J]. J Natl Cancer Inst, 2010, 102( 3): 202- 206. DOI: 10.1093/jnci/djp459.
[36]	TSILIDIS KK, BRANCHINI C, GUALLAR E, et al. C-reactive protein and colorectal cancer risk: A systematic review of prospective studies[J]. Int J Cancer, 2008, 123( 5): 1133- 1140. DOI: 10.1002/ijc.23606.
[37]	BJÖRNTORP P. Metabolic implications of body fat distribution[J]. Diabetes Care, 1991, 14( 12): 1132- 1143. DOI: 10.2337/diacare.14.12.1132.
[38]	HOTAMISLIGIL GS. Foundations of immunometabolism and implications for metabolic health and disease[J]. Immunity, 2017, 47( 3): 406- 420. DOI: 10.1016/j.immuni.2017.08.009.
[39]	KOLB R, SUTTERWALA FS, ZHANG WZ. Obesity and cancer: Inflammation bridges the two[J]. Curr Opin Pharmacol, 2016, 29: 77- 89. DOI: 10.1016/j.coph.2016.07.005.
[40]	PFALZER AC, NESBETH PC, PARNELL LD, et al. Diet-and genetically-induced obesity differentially affect the fecal microbiome and metabolome in Apc1638N mice[J]. PLoS One, 2015, 10( 8): e0135758. DOI: 10.1371/journal.pone.0135758.
[41]	BAIDAL JA WOO, LAVINE JE. The intersection of nonalcoholic fatty liver disease and obesity[J]. Sci Transl Med, 2016, 8( 323): 323rv1. DOI: 10.1126/scitranslmed.aad8390.
[42]	NEUSCHWANDER-TETRI BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites[J]. Hepatology, 2010, 52( 2): 774- 788. DOI: 10.1002/hep.23719.
[43]	NAKAGAWA H, UMEMURA A, TANIGUCHI K, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development[J]. Cancer Cell, 2014, 26( 3): 331- 343. DOI: 10.1016/j.ccr.2014.07.001.
[44]	PARK EJ, LEE JH, YU GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression[J]. Cell, 2010, 140( 2): 197- 208. DOI: 10.1016/j.cell.2009.12.052.
[45]	MICHAUD DS. Obesity and pancreatic cancer[J]. Recent Results Cancer Res, 2016, 208: 95- 105. DOI: 10.1007/978-3-319-42542-9_6.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (417) PDF downloads(39)

Association of Chinese visceral adiposity index and high-sensitivity C-reactive protein with the risk of digestive malignancies

DOI: 10.12449/JCH250723

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Association of Chinese visceral adiposity index and high-sensitivity C-reactive protein with the risk of digestive malignancies

DOI: 10.12449/JCH250723

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content